Evogene Ltd. (TLV:EVGN)

Market Cap	45.03M
Revenue (ttm)	25.19M
Net Income (ttm)	-56.63M
Shares Out	8.71M
EPS (ttm)	-9.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,508
Average Volume	166,609
Open	543.00
Previous Close	516.70
Day's Range	529.00 - 548.00
52-Week Range	357.30 - 2,482.00
Beta	1.37
RSI	56.49
Earnings Date	May 20, 2025

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 117
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: EVGN

Financial Performance

In 2024, Evogene's revenue was $8.51 million, an increase of 50.90% compared to the previous year's $5.64 million. Losses were -$16.49 million, -30.96% less than in 2023.

Financial numbers in USD